{"cluster": 62, "subcluster": 4, "abstract_summ": "Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19.However, there are currently no effective drugs targeting 2019-nCoV. Drug repurposing, represented as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery.Summary Since the outbreak in 2019, researchers are trying to find effective drugs against the SARS-CoV-2 virus based on de novo drug design and drug repurposing.However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2.We employed transcriptional analysis to uncover potential antiviral drugs from natural products or FDA approved drugs.", "title_summ": "CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative ModelsSAveRUNNER: a network-based algorithm for drug repurposing and its application to COVID-19Targeting SARS-CoV-2 with AI- and HPC-enabled Lead Generation: A First Data ReleaseAdaptive Invariance for Molecule Property PredictionComputational Drug Repositioning and Elucidation of Mechanism of Action of Compounds against SARS-CoV-2PaccMann$^{RL}$ on SARS-CoV-2: Designing antiviral candidates with conditional generative modelsNetwork Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19Drug repurposing prediction for COVID-19 using probabilistic networks and crowdsourced curationScreening of Therapeutic Agents for COVID-19 using Machine Learning and Ensemble Docking SimulationsPrediction of potential commercially inhibitors against SARS-CoV-2 by multi-task deep modelRepurpose Open Data to Discover Therapeutics for COVID-19 using Deep LearningRepositioning of 8565 existing drugs for COVID-19Accelerating Antimicrobial Discovery with Controllable Deep Generative Models and Molecular DynamicsReview of COVID-19 Antibody TherapiesAccelerating drug repurposing for COVID-19 via modeling drug mechanism of action with large scale gene-expression profilesPredicting potential drug targets and repurposable drugs for COVID-19 via a deep generative model for graphsIdentification of Repurposal Drugs and Adverse Drug Reactions for Various Courses of Coronavirus Disease 2019 (COVID-19) Based on Single-cell RNA Sequencing DataMachine-Learning Driven Drug Repurposing for COVID-19Large-scale ligand-based virtual screening for SARS-CoV-2 inhibitors using deep neural networksAttacking COVID-19 Progression using Multi-Drug Therapy for Synergetic Target EngagementExploring the SARS-CoV-2 virus-host-drug interactome for drug repurposingUsing Bayesian Optimization to Accelerate Virtual Screening for the Discovery of Therapeutics Appropriate for Repurposing for COVID-19A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trialsCausal Network Models of SARS-CoV-2 Expression and Aging to Identify Candidates for Drug RepurposingPredicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning modelMachine intelligence design of 2019-nCoV drugsRepositioning of 8565 Existing Drugs for COVID-19Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing DataAn OpenData portal to share COVID-19 drug repurposing data in real timeDrug repositioning: a brief overviewCORDITE: the curated CORona Drug InTERactions database for SARS-CoV-2Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2Potentially highly potent drugs for 2019-nCoVDeep Learning Based Drug Screening for Novel Coronavirus 2019-nCovPotential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirusAdvanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approachTherapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput ScreeningPredicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning modelPotential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicinesMorphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19Intense bitterness of molecules: machine learning for expediting drug discoveryDeciphering complex mechanisms of resistance and loss of potency through coupled molecular dynamics and machine learningRapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputingRepurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and DockingNetwork-based Drug Repurposing for Human CoronavirusMachine Learning Models Identify Inhibitors of SARS-CoV-2Genetic Profiles in Pharmacogenes Indicate Personalized Drug Therapy for COVID-19An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferonDatabase for drug metabolism and comparisons, NICEdrug.ch, aids discovery and designIdentification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2Multi-omics study revealing tissue-dependent putative mechanisms of SARS-CoV-2 drug targets on viral infections and complex diseasesA data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19.Review of COVID-19 Antibody Therapies.Therapeutic targets and computational approaches on drug development for COVID-19.Shape-based Machine Learning Models for the potential Novel COVID-19 protease inhibitors assisted by Molecular Dynamics Simulation.An up-to-date overview of computational polypharmacology in modern drug discovery.", "title_abstract_phrases": "Predicting potential drug targets and repurposable drugs for COVID-19 via a deep generative model for graphsCoronavirus Disease 2019 (COVID-19) has been creating a worldwide pandemic situation.Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19.We employed transcriptional analysis to uncover potential antiviral drugs from natural products or FDA approved drugs.In this study, we have identified 4 small molecular drugs with high binding capacity with SARS-CoV main protease by high-throughput screening based on the 8,000 clinical drug libraries, all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of 2019-nCoV.Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning modelThe infection of a novel coronavirus found in Wuhan of China (2019-nCoV) is rapidly spreading, and the incidence rate is increasing worldwide.However, there are currently no effective drugs targeting 2019-nCoV. Drug repurposing, represented as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery."}